-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$40.0039.76% Upside
Denali Therapeutics Inc. Frequently Asked Questions
-
What analysts cover Denali Therapeutics Inc.?
Denali Therapeutics Inc. has been rated by research analysts at Bank of America Securities, B.Riley Financial, Goldman Sachs, Stifel Nicolaus, UBS in the past 90 days.